Capricor Therapeutics is a San Diego-based clinical-stage biotechnology company that is developing cell therapy and extracellular vesicle-based treatments for Duchenne muscular dystrophy and other rare diseases, and the company is in the middle of a fiscal second quarter that demonstrates the kind of platform-validation profile the cell-therapy biotech cohort has been waiting for. H1 2026 total operating expenses of $79.7 million were 51.3 percent above the prior-year period's $52.7 million, with the increase driven by the R&D expense growth, the G&A expense growth, and the platform-expansion execution. The principal question for the next four quarters is whether the company can advance the deramiocel program through the regulatory approval and produce the commercial-launch profile, and whether the cash runway is sufficient to fund the commercial-launch execution.